TY - JOUR T1 - Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multi-national network cohort study JF - medRxiv DO - 10.1101/2020.07.17.20156059 SP - 2020.07.17.20156059 AU - Jennifer C.E. Lane AU - James Weaver AU - Kristin Kostka AU - Talita Duarte-Salles AU - Maria Tereza F. Abrahao AU - Heba Alghoul AU - Osaid Alser AU - Thamir M Alshammari AU - Carlos Areia AU - Patricia Biedermann AU - Juan M. Banda AU - Edward Burn AU - Paula Casajust AU - Kristina FiĊĦer AU - Jill Hardin AU - Laura Hester AU - George Hripcsak AU - Benjamin Skov Kaas-Hansen AU - Sajan Khosla AU - Spyros Kolovos AU - Kristine E. Lynch AU - Rupa Makadia AU - Paras P. Mehta AU - Daniel R. Morales AU - Henry Morgan-Stewart AU - Mees Mosseveld AU - Danielle Newby AU - Fredrik Nyberg AU - Anna Ostropolets AU - Rae Woong Park AU - Albert Prats-Uribe AU - Gowtham A. Rao AU - Christian Reich AU - Peter Rijnbeek AU - Anthony G. Sena AU - Azza Shoaibi AU - Matthew Spotnitz AU - Vignesh Subbian AU - Marc A. Suchard AU - David Vizcaya AU - Haini Wen AU - Marcel de Wilde AU - Junqing Xie AU - Seng Chan You AU - Lin Zhang AU - Simon Lovestone AU - Patrick Ryan AU - Daniel Prieto-Alhambra AU - on behalf of OHDSI-COVID-19 consortium Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/07/2020.07.17.20156059.abstract N2 - Objectives Concern has been raised in the rheumatological community regarding recent regulatory warnings that hydroxychloroquine used in the COVID-19 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation, or psychosis associated with hydroxychloroquine as used for rheumatoid arthritis (RA).Methods New user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and US). RA patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine (active comparator) and followed up in the short (30-day) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation, and hospitalization for psychosis. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate database-specific calibrated hazard ratios (HR), with estimates pooled where I2<40%.Results 918,144 and 290,383 users of hydroxychloroquine and sulfasalazine, respectively, were included. No consistent risk of psychiatric events was observed with short-term hydroxychloroquine (compared to sulfasalazine) use, with meta-analytic HRs of 0.96 [0.79-1.16] for depression, 0.94 [0.49-1.77] for suicide/suicidal ideation, and 1.03 [0.66-1.60] for psychosis. No consistent long-term risk was seen, with meta-analytic HRs 0.94 [0.71-1.26] for depression, 0.77 [0.56-1.07] for suicide/suicidal ideation, and 0.99 [0.72-1.35] for psychosis.Conclusions Hydroxychloroquine as used to treat RA does not appear to increase the risk of depression, suicide/suicidal ideation, or psychosis compared to sulfasalazine. No effects were seen in the short or long term. Use at higher dose or for different indications needs further investigation.TRIAL REGISTRATION Registered with EU PAS; Reference number EUPAS34497 (http://www.encepp.eu/encepp/viewResource.htm?id=34498). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine.WHAT IS ALREADY KNOWN ON THIS TOPICRecent regulatory warnings have raised concerns of potential psychiatric side effects of hydroxychloroquine at the doses used to treat COVID-19, generating concern in the rheumatological communitySerious psychiatric adverse events such as suicide, acute psychosis, and depressive episodes have been identified by the US Food and Drug Administration (FDA) adverse events reporting system and at case report levelWHAT THIS STUDY ADDSThis is the largest study on the neuro-psychiatric safety of hydroxychloroquine to date, including >900,000 users treated for their RA in country-level or private health care systems in Germany, the UK, and the USWe find no association between the use of hydroxychloroquine and the risk of depression, suicide/suicidal ideation, or severe psychosis compared to sulfasalazineHOW MIGHT THIS IMPACT ON CLINICAL PRACTICEOur data shows no association between hydroxychloroquine treatment for RA and risk of depression, suicide or psychosis compared to sulfasalazine. These findings do not support stopping or switching hydroxychloroquine treatment as used for RA due to recent concerns based on COVID-19 treated patients.Competing Interest StatementMiss Lane reports grants from the Medical Research Council (MR/K501256/1) and Versus Arthritis (21605), outside of the submitted work. Prof Prieto-Alhambra reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; public-private partnerships within IMI including EHDEN and EMIF consortia and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. Mr. Weaver, Dr. Conover, Dr. Hardin, Dr Rao, Dr. Schuemie, Mr. Sena, Dr. Shoaibi, Dr. Ryan are employees of Janssen Research and Development and shareholders of Johnson & Johnson. Dr. DuVall reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research, outside the submitted work. Dr. Hripcsak reports grants from US National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work; Dr. Kaas-Hansen reports grants from Innovation Fund Denmark (5153-00002B), grants from Novo Nordisk Foundation (NNF14CC0001), outside the submitted work. Dr. Khosla reports employment from AstraZeneca, outside the submitted work;Prof van der Lei, Dr de Wilde and Mr Mosseveld report grants from Innovative Medicines Initiative; Dr. Margulis reports she is an employee of RTI Health Solutions, a unit of RTI International, an independent, nonprofit research organization that does work for government agencies and pharmaceutical companies. This work was not an RTI assignment; and she participated as a citizen scientist. Dr. Morales is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports funding support from the NIHR, Chief Scientist Office and Tenovus Scotland for research unrelated to this work. Dr. Nyberg reports employment from AstraZeneca, outside the submitted work; Dr. Prats-Uribe reports grants from Fundacion Alfonso Martin Escudero, grants from Medical Research Council, outside the submitted work; Dr Rijnbeek reports grants from Innovative Medicines Initiative and from Janssen Research and Development, during the conduct of the study; Dr. Morgan-Stewart, Dr Torre Ms Seager and Ms Kostka are employees of IQVIA, outside of submitted work. Dr. Suchard reports grants from US National Science Foundation, grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, during the conduct of the study. Dr. Vizcaya is an employee of Bayer; outside submitted work. Dr. You reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study;All other authors declare no competing interests.Clinical TrialRegistered with EU PAS; Reference number EUPAS34497 (http://www.encepp.eu/encepp/viewResource.htm?id=34498)Clinical Protocols https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine . http://www.encepp.eu/encepp/viewResource.htm?id=34498 Funding StatementA full funding statement is included in the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:AmbEMR-This is a retrospective database study on de-identified data and is deemed not human subject research. Approval is provided for OHDSI community studies. CCAE-New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research. CPRD-Approval for CPRD was provided by the Independent Scientific Advisory Committee (ISAC).This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. The protocol for this study ( 20_059R) was approved by the Independent Scientific Advisory Committee (ISAC). DA Germany-This is a retrospective database study on de-identified data and is deemed not human subject research. Approval is provided for OHDSI community studies. IMRD-The present study is filed and under review for Scientific Review Committee for institutional adjudication. Due to the public health imperative of information related to these data, approval is provided for this publication. IPCI-The present study was approved by the Scientific and Ethical Advisory Board of the IPCI project (project number: 4/2020). JMDC-New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research. MDCD-New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research. MDCD-New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research. Open Claims-This is a retrospective database study on de-identified data and is deemed not human subject research. Approval is provided for OHDSI community studies. Clinformatics-New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research. Optum EHR- New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study was conducted as a distributed database network analysis. To protect patient privacy, all patient-level data were maintained securely behind institutional firewalls. Analysis code was downloaded and executed by each participating data partner, which generated only aggregate summary statistics (cohort counts, model coefficients) which were then centralized and synthesized in preparation of this manuscript. All aggregate summary statistics produced have been made publicly available at: https://data.ohdsi.org/Covid19EstimationHydroxychloroquine2/. https://data.ohdsi.org/Covid19EstimationHydroxychloroquine2/. ER -